Drugs / Teva Ad4/Ad7
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03160339 Comparator | May → Nov 2017 | adenoviridae infectious disease | Emergent BioSolutions | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teva Ad4/Ad7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03160339 ↗ |
| Modality | Vaccine | “Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine” NCT03160339 ↗ |
| Route | Oral | “Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration.” NCT03160339 ↗ |